MAIN ARTICLE
A quarter powered largely by pricing
BASF's third-quarter figures reveal the importance of pricing in a volatile market for industrial materials. Sales of €16.4 billion compared with €14.3 billion a year earlier. The company attributed the 14% increase mainly to prices rising 12%, alongside a 2% increase in volumes. Reuters reported that the sales figure was almost 5% ahead of the average expectation among analysts surveyed by the group. More expensive products, however, should not be mistaken for an equivalent increase in the amount customers purchase.
Earnings before interest, taxes, depreciation and amortisation, excluding special items, reached roughly €1.6 billion, 15% above the prior-year quarter. BASF now forecasts full-year adjusted EBITDA of €7.4 billion–€7.8 billion, compared with €6.9 billion–€7.7 billion in July. The notably higher bottom end of that range suggests management has more confidence in the earnings already secured, even while acknowledging that the operating environment remains unpredictable.
Evonik and the limits of an ambitious deal
The quarterly results have not displaced the takeover question at the heart of investor attention. Two people familiar with the talks told Reuters that BASF had increased its proposed price for Evonik from around €22.15 to €24 per share, placing an approximately €11.18 billion value on its German rival. An earlier offer worth about €10.3 billion was reportedly rejected. These figures describe a reported negotiation, not an agreed or completed acquisition.














